TSIO 2006

Workshop "Turning subjective into objective" A new tool for the aesthetic evaluation of breast cancer conservative treatment
(BCCT.core 1.0)

Portugal, Porto, 18th November 2006

Organizing Committee

. Maria João Cardoso
. Jaime S. Cardoso
. UPIN – Universidade do Porto Inovação

Participants

Conny Vrieling, Radiation Oncology
The Netherlands Cancer Institute, Amsterdam, The Netherlands

David Christie
Radiation Oncologist, East Coast Cancer Center, Tugun
Associate Professor, Bond University, Queensland, Australia

Douglas Macmillan,
Consultant Breast Surgeon and Associate Clinical Director
Nottingham Breast Institute, UK

Florian Fitzal,
Surgeon, Medical University Vienna Waehringer, Austria

Janez Žgajnar,
Breast Surgeon, Institute of Oncology, Ljubljana, Slovenia

Jørgen Johansen,
Chief Physician, Oncology Department, Odense University Hospital, Denmark

José Rosa de Almeida,
Plastic and Reconstructive Surgery, Portuguese Institute of Oncology, Lisbon Centre, Portugal

Lea Regolo,
Breast Surgeon, Fondazione Salvatore Maugeri, Surgical Department. Pavia, Italy

Lise Barreau,
Oncoplastic Breast Surgeon, Institute Gustave Roussy, Villejuif, France

Maria Piera Mano,
Surgeon, University of Turin, CPO Piemonte, Italy

Mário Bernardo
Breast Surgeon, Professor of Oncology, Faculdade de Ciências Médicas, Universidade Nova, Lisboa, Portugal

Natália Amaral
Gynaecologist, Department of Gynaecology, Obstetrics and Reproduction Medicine, Hospital da Universidade, Coimbra, Portugal

Susy Costa
General and Breast Surgeon, Hospital de São João, Faculdade de Medicina do Porto, Portugal


Collaborators

José Luis Fougo
General and Oncologic Surgeon, Portuguese Institute of Oncology, Porto Center, Portugal

Luís Filipe Pinto de Almeida Teixeira
Unidade de Telecomunicações e Multimédia, INESC Porto, Portugal

Invited Observer

Mariano Tomatis
CPO Piemonte, Italy

Sponsors

Faculdade de Medicina da Universidade do Porto
INESC Porto
Fundação Calouste Gulbenkian
Fundação para a Ciência e a Tecnologia
Champalimaud Foundation
AstraZeneca
Novartis
Sanofi Aventis
Roche